NCT05335993 2026-04-03
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
CanariaBio Inc.
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT03783949 2025-06-11
EUDARIO
Universitaire Ziekenhuizen KU Leuven
Phase 2 Completed
NCT05126342 2025-04-06
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
AGO Research GmbH
Phase 2 Withdrawn
NCT03891576 2025-01-17
Newton
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT03759600 2024-07-16
Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer
Takeda
Phase 2 Completed
NCT03759587 2024-06-07
Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer
Takeda
Phase 2 Completed
NCT05065021 2024-01-17
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
Phase 2 Unknown
NCT03983226 2022-03-18
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
Shanghai Gynecologic Oncology Group
Phase 2 Recruiting
NCT04556071 2020-11-10
AVANIRA3
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown